LC-MS/MS monitoring of the colorectal carcinoma cellular uptake and entrapment of sorafenib and its N-oxide active metabolite

Copyright © 2022 Elsevier B.V. All rights reserved..

Sorafenib (SOR) is a multikinase inhibitor with a mild activity against colorectal cancer cells due to multi-drug resistance mechanisms. Potentiated SOR activity was expected upon combination with some ginger derived compounds due to their interference with intracellular drug metabolism. Studying such combination necessitates the development of a sensitive validated LC-MS/MS method for the determination of intra and extracellular concentration of SOR and its N-oxide metabolite (SNX) in colorectal cancer cells. SOR, SNX and the internal standard (diclofenac sodium) were efficiently separated on Eclipse plus C18 column (3.0 ×150 mm, 5 µm) using isocratic elution with acetonitrile and 0.01 M ammonium formate aqueous solution containing 0.1% formic acid (69:31, v/v). Sample pretreatment using solid phase extraction was optimized and the mean percent recoveries were more than 97.01% for both analytes. Detection was conducted at positive ion multiple reaction monitoring (MRM) mode and the monitored mass transitions were 465.2 → 252.2 for SOR and 481.1 → 286.0 for SNX. The method was linear over the range 0.25 - 200.00 ng/mL (r2 ≥ 0.9992) for SOR and 0.10 - 125.00 ng/mL (r2 ≥ 0.9990) for SNX in both intra and extracellular matrices. The lower limits of quantification (LLOQ) were 0.25 and 0.10 ng/mL for SOR and SNX, respectively. Accuracies were within 94.25 - 109.45% and precision CV values did not exceed 7.63%. The method was able to monitor the cellular uptake and entrapment of both analytes and to prove the positive effect of the ginger derived compounds on SOR activity.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:213

Enthalten in:

Journal of pharmaceutical and biomedical analysis - 213(2022) vom: 10. Mai, Seite 114687

Sprache:

Englisch

Beteiligte Personen:

Elawady, Tarek [VerfasserIn]
Al-Abd, Ahmed M [VerfasserIn]
Khedr, Alaa [VerfasserIn]
El-Enany, Nahed [VerfasserIn]
Belal, Fathalla [VerfasserIn]

Links:

Volltext

Themen:

9ZOQ3TZI87
Cell line
Journal Article
LC-MS/MS
Oxides
Solid phase extraction
Sorafenib
Sorafenib N-oxide

Anmerkungen:

Date Completed 05.04.2022

Date Revised 05.04.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.jpba.2022.114687

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM33771617X